EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Transforming the Management of Oligometastatic Non-Small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy

Yohei Kawaguchi, Satoshi Takahashi, Yoshihisa Shimada, Yujin Kudo iD, Norihiko Ikeda

Cancers · 12.09.2025 · 17 (18) · 2982

DOI: 10.3390/cancers17182982 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.09.2025. Verfasst von Yohei Kawaguchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Tokyo Medical University Hospital, Tokyo 1600023, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oligometastatic non-small cell lung cancer (omNSCLC) is increasingly recognized as a clinically actionable subset, characterized by a limited number of metastatic lesions and the potential to benefit from combined systemic and local treatments. Advances in systemic therapy, particularly immune checkpoint inhibitors (ICI) and molecular targeted agents, have led to prolonged disease control in selected patients. Prospective clinical trials have shown that incorporating local therapy into systemic treatment can improve progression-free and overall survival outcomes in carefully selected patients with metastatic disease. Radiotherapy has increasingly become the preferred modality for local consolidation, especially when surgical options are limited or impractical. Key factors influencing treatment selection include biomarker status, the number and distribution of metastases, and the response to the initial systemic therapy. The optimal timing and modality of local interventions remain under investigation. This review examines the evolving treatment strategies for omNSCLC, primarily from the perspective of systemic therapies. By contextualizing local treatment modalities within the framework of immunotherapy and targeted therapy, we reinterpret current evidence to clarify when and how local therapy contributes to long-term disease control.

Schlagwörter

Stichwörter der Autor:innen

local ablative therapynon-small cell lung canceroligometastatic lung cancersynchronous metastasis

Autor:innen und Institutionen

  • Department of Surgery, Tokyo Medical University Hospital, Tokyo 1600023, Japan.

ORCID-Profile: Yujin Kudo

Zitieren

APA

Kawaguchi, Y., Takahashi, S., Shimada, Y., Kudo, Y., & Ikeda, N. (2025). Transforming the Management of Oligometastatic Non-Small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy. Cancers, 17(18), 2982. https://doi.org/10.3390/cancers17182982

Vancouver

Kawaguchi Y, Takahashi S, Shimada Y, Kudo Y, Ikeda N. Transforming the Management of Oligometastatic Non-Small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy. Cancers. 2025;17(18):2982. doi:10.3390/cancers17182982

BibTeX
@article{Kawaguchi2025,
  author = {Kawaguchi, Yohei and Takahashi, Satoshi and Shimada, Yoshihisa and Kudo, Yujin and Ikeda, Norihiko},
  title = {Transforming the Management of Oligometastatic Non-Small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {18},
  pages = {2982},
  doi = {10.3390/cancers17182982}
}
Kostenlos starten →